Pre-surgery low-dose azacitidine for high-risk early breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies whether giving a low dose of azacitidine before surgery can shrink or control high-risk early breast cancer. It’s meant for adults whose cancer has not yet spread to distant organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can sign consent for the study
- You can move about normally (ECOG 0–2)
- Your breast cancer was confirmed by biopsy and is early stage (T1a–T3, no distant spread)
- Your tumor is either triple-negative breast cancer, or hormone-receptor positive but with high-risk features (like HER2, lymph node involvement, certain gene tests, or PR-negative)
- Your blood counts and liver/kidney tests are adequate, checked within 30 days of enrolling
- You have not had cancer treatment for this current breast cancer (like chemo, immunotherapy, radiation to the breast/underarm area)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This Phase 2 study checks whether adding a personalized (biomarker-matched) medicine after standard chemotherapy and surgery lowers the risk of breast cancer coming back. Your study drug choice depends on tumor test results (from your tumor’s genetics and immune markers).
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
This trial tests a new drug combination given before surgery for early-stage, hormone receptor-positive breast cancer. It aims to see if this approach can improve outcomes for patients with high-risk features.
This trial tests a new drug (SHR-A1811) alone or with letrozole given before surgery to shrink early-stage breast cancer that is hormone receptor-positive and HER2-low. It may help make surgery more effective.
This study tests whether a low-dose chemotherapy pill called capecitabine can help prevent breast cancer from coming back in patients whose cancer shows signs of remaining disease (called MRD) despite standard treatment. The trial focuses on hormone-receptor-positive, HER2-negative breast cancers.
Hear when a new Breast Cancer Invasive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.